The levels of IgA are plotted in Fig 1. Four of the 14 penicillamine-treated patients had consistently low levels and the mean for all patients in this group is lower than that for the controls.
It has been possible to investigate only small numbers of patients with cystinuria treated with penicillamine, but the results suggest that there may be a group of patients who react to treatment by lowering the level of IgA. DISCUSSION Dr I A Jaffe (New York): Dr Stephens' presenta-tion1 illustrates precisely one of the major problems encountered with penicillamine. He showed an ascending dosage up to 3000 mg a day over a 21-day period, and a decreasing urinary cystine excretion over a comparable period. The impression given is that as the penicillamine goes up the urinary cystine goes down. In fact, a third event had taken place: namely, 21 days have elapsed. How do we know what would happen if a lower dose was chosen, say, 750 mg or 1000 mg, and it was held at that level for longer? There is nothing magical about 21 days, because a lifetime of treatment is required. Since the cystine pool is large and the penicillamine-cysteine mixed disulphide is formed continuously, how do we know that we might not achieve the same reduced level of urinary cystine at this lower dosage, within a greater span of time? Dr Stephens: This is something we do not know at present, and it is something which we must do. Many of these patients have stones which we are trying to dissolve and, in that situation, we feel that the cystine concentration should be brought down as fast as possible. The next investigation we hope to do is to try to determine the smallest dose of penicillamine on which these patients can be managedbut this would have to be on the patients without stones. Dr Walshe: First, about the immunoglobulins, we have one Wilson's disease patient with agammaglobulinaemia. Unfortunately, I do not know whether or not this is drug-induced, because she did not have a proper work-up before treatment was startedsomething every patient should have. She was originally a patient at 'St Elsewhere's Hospital', and we do not know her initial serum protein. Her parents live in Teheran, so are not available for study, and we do not know what the rest of her family is like. We rather suspect that the agammaglobulinaemia is drug-induced.
Secondly, with respect to the lack of interdisciplinary cooperation, here we have the people dealing with cystinuria carrying out a fascinating ' see p 24
Serum Apart from its clinical use in Wilson's disease, cystinuria and rheumatoid arthritis, penicillamine has been used in the laboratory to reduce IgM into subunits. Because of this it was decided to examine the sera of patients undergoing longterm treatment with penicillamine to see if there was any in vivo effect on the immunoglobulins.
Fourteen patients with cystinuria were investigated, all of whom had been treated with Dpenicillamine for more than five years (dose range: 1125-3000 mg/24 h). Immunoglobulins were estimated once annually for periods of up to six years. For control purposes, immunoglobulin levels were estimated in 8 patients with cystinuria before treatment with penicillamine. As the number of control observations is limited, further comparison has been made in 19 patients with other types of renal stone, the immunoglobulin levels being estimated on one occasion only.
In the case of IgG there is no apparent difference in level between any of the groups of patients. The levels of IgM in the patients treated with penicillamine tend to lie in the lower part of the normal range, though with a limited number of observations no significance can be attached. biochemical study, out of which they are apparently getting nothing. Penicillamine is being given to patients with normal copper balance, yet we are not told what happens to the blood copper and cwruloplasmin levels. I have one patient with cystinuria whom I inherited from a surgeon. When she had been on penicillamine for about six months, without supplements, her serum copper and serum cwruloplasmin went down to extremely low levels. After one month on a small copper sulphate supplement these levels went back to normal.
F
If only those who are treating cystinurics would measure the serum copper and serum cmruloplasmin before starting treatment and regularly at six-monthly intervals afterwards to find out what happens it would be extremely interesting.
Dr J C Crawhall (Montreal): In reply to Dr Jaffe's comment, there has been anecdotal information about the cystine pool. First, if the amount of cysteine moiety that is excreted in the urine of patients on penicillamine is added up, the total amount excreted is less than that before they took the drug. Although there is this exchange reaction taking place, another factor of some sort must also be involved.
Secondly, in some studies -I believe not publishedthere is evidence that if a patient is on penicillamine for a length of time and is then taken off the drug, the cystine excretion does not immediately return to the pretreatment level, but stays at about two-thirds of it. I do not know exactly when it does return, but it is over a period of months.
With respect to Dr Walshe's remarks about copper balance studies, results for 2 cystinuric patients on penicillamine have been published (Bostrom H & Wester P 0, 1967, Acta medica Scandinavica 181, 475).
Dr D R Stanworth (Birmingham): In response to Dr Walshe's statement about drug-induced agammaglobulinemia, we have had one rheumatoid patient on penicillamine who developed an IgA deficiency. After withdrawal of the drug the IgA eventually became completely negativebut here again we cannot say whether this would have occurred anyway. Dr Stephens mentioned the immunoglobulin levels in cystinuria. The effects in the rheumatoid patients that we have studied are probably not so marked as those he found. There is some reduction in IgA, but usually IgA levels in rheumatoid patients are high initially and tend to come down into the normal range. There is some decrease in IgM in some patients, but Dr Stephens seems to have found a uniform reduction effect. I presume that the starting value was taken into consideration? He said that all his points were means of severalwere all these measured when the patients were on the drug? Dr Stephens: Measurements on the treated cystinurics were all while on the drug, but none of them had pretreatment levels measured. The cystinuric controls were all separate patients who came after the study had been started. Dr Stanworth: Of all the immunoglobulins we have looked at, certainly in the rheumatoid group, the penicillamine effect on IgE seems to be the most interesting.
Dr H Berry (London): Just for completeness, we looked at the immunoglobulins and tried to correlate them in our rheumatoid patients about three or four years ago. We found a serial fall in IgA, with smaller falls in IgG and IgM, but surprisingly we could find no correlation between these falls and any of the clinical parameters.
Dr H E Amos (Carshalton): The interest in immunoglobulin levels seems to be on the effect of penicillamine on the metabolism of the formed immunoglobulin. Has anyone studied the effect of penicillamine on the synthesis of immunoglobulin? I wonder whether the reduction in immunoglobulin is matched by an increased synthesis in an effort to maintain the status quo.
Dr A M Davison (Leeds): This has been studied in experimental animals, in some of which there is apparently a delayed production of immunoglobulin. This ties up beautifully with what has just been discussed.
I should like to ask Dr Stephens1 about his groups of patients with proteinuria: those with less than 1 g, 1-5 g, and over 5 g. Is he inferring that these are different speciesdifferent populations, if I may use that word -of patient responses? Is he suggesting that patients on penicillamine with less than 1 g of protein a day do not have a penicillamine-induced protein loss, Dr R Grahame (London): With reference to a remark made by Mr Purkiss about a patient whom it was possible to desensitize against penicillamine, how easy is it to desensitize to penicillamine in general and in this particular patient? Was it an early or late rash that responded to the treatment ?
Mr Purkiss: The patient developed a rash after about two weeks' treatment. The penicillamine was withdrawn, the patient was given prednisolone -I cannot recall the dosefor about two weeks, after which the penicillamine was reinstituted slowly, 250 mg then 500 mg, over another two weeks. The rash disappeared, and since then the prednisolone has been withdrawn and there have been no further problems. I do not know whether this would always work Dr I Sternlieb (New York): After observing a remarkable drop in the concentration of IgA in a patient with Wilson's disease treated with Dpenicillamine, Dr L-A Hanson from Goteborg requested samples of serum from our treated patients. To his surprise he found normal IgA levels in all eight specimens from our patients treated for up to 14 years.
On another subject we face a problem in semantics: although I am not a dermatologist, I feel strongly that the lesions that were shown to us earlier are not those of 'epidermolysis bullosa'. They are, however, characteristic of 'penicillamine dermatopathy' as described by us in 1964 (Sternlieb r & Scheinberg I H, 1964 . This lesion is dose-related and occurs in patients receiving high doses of D-penicillamine. By contrast, lesions truly resembling epidermolysis bullosa, characterized by large fluid-filled blisters, occurring on the soles or on the dorsa of feet, were seen by us in a few patients about 12-15 years ago, but not since. This was at the time when D,L-penicillamine was the only drug available to us. Dr Stanworth: In relation to that remark, there is an interesting report from Scandinavia, where a large number of apparently healthy individuals have been screened for IgA. A certain percentage of IgA deficiency was found and there has been an increased incidencea high incidenceof association of autoimmune diseases in these individuals. It has been suggested that individuals with low IgA, or no IgA, even though apparently normal, should be considered as potential problems for the future. This is of interest in relation to what has been said. but that the proteinuria is due to infection, stones or whatever? That would certainly not be our experience because we find significant ultrastructural abnormalities in the kidney with very low amounts of protein in the urine. I do not think that this can be said to represent different groups.
What is very interesting here is that if there is delay in immunoglobulin production there will be a prolonged period following an antigen in which there will be soluble antigen/antibody complexes present. These are just the ones which get laid down in the kidney. It is possible, therefore, that interference with immunoglobulins, IgM and IgG, may be the pathogenetic mechanism for production of nephropathy. I realize that statement is a little high-flown, but it is a possibility.
Dr Stephens: With regard to the proteinuria, I do not have any evidence, other than clinical evidence, to separate the patients into three groups. I was suggesting that those with less than 1 g might have proteinuria from other causes, such as infection and stones, but biopsies have not been done on these patients. Neither have we biopsies taken before patients started to have clinical problems, which means that any biopsy would also be confused by any obstructive damage that might have occurred.
About the immunoglobulins and the possible progression to the nephrotic syndrome, one of our 4 patients with heavy proteinuria is worthy of comment.
This patient originally had 18.6 g of protein in the urine while on penicillamine. After stopping the drug the proteinuria disappeared. About one year later he was restarted on the very small dose of 250 mg a dayat least, we considered it a low dose. Although he was lost to follow-up for another year he was maintained on that dose. On later re-referral he had many clinical symptoms of stones. The 'enicillamine was gradually increased to 3 g a day, with no proteinuria for three months. He then developed a small amount of proteinuria, rising to 2 g a day. The penicillamine was reduced slightly, from 3 g to 2 g daily, and the proteinuria disappeared.
Immunoglobulins were measured during this latter period of treatment and were all found to be normal. But we do not know what they were like either during or before his nephrotic syndrome.
Professor McCance: It is clear that many aspects of this must be looked at when patients are being treated.
